Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.
Risk and Volatility
Kyverna Therapeutics has a beta of 3.72, meaning that its share price is 272% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Earnings and Valuation
This table compares Kyverna Therapeutics and Contineum Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyverna Therapeutics | $7.03 million | 40.79 | -$127.48 million | ($3.68) | -1.80 |
| Contineum Therapeutics | $50.00 million | 6.66 | -$42.26 million | ($2.20) | -5.40 |
Contineum Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for Kyverna Therapeutics and Contineum Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyverna Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| Contineum Therapeutics | 1 | 0 | 6 | 2 | 3.00 |
Kyverna Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 186.58%. Contineum Therapeutics has a consensus price target of $22.20, suggesting a potential upside of 86.87%. Given Kyverna Therapeutics’ higher probable upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Contineum Therapeutics.
Institutional & Insider Ownership
18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.0% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Kyverna Therapeutics and Contineum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyverna Therapeutics | N/A | -64.98% | -56.17% |
| Contineum Therapeutics | N/A | -29.75% | -28.08% |
Summary
Contineum Therapeutics beats Kyverna Therapeutics on 8 of the 14 factors compared between the two stocks.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
